olmesartan has been researched along with olmesartan medoxomil in 32 studies
| Studies (olmesartan) | Trials (olmesartan) | Recent Studies (post-2010) (olmesartan) | Studies (olmesartan medoxomil) | Trials (olmesartan medoxomil) | Recent Studies (post-2010) (olmesartan medoxomil) |
|---|---|---|---|---|---|
| 841 | 185 | 554 | 459 | 119 | 203 |
| Protein | Taxonomy | olmesartan (IC50) | olmesartan medoxomil (IC50) |
|---|---|---|---|
| ATP-binding cassette sub-family C member 3 | Homo sapiens (human) | 2 | |
| Bile salt export pump | Homo sapiens (human) | 4.73 | |
| Solute carrier organic anion transporter family member 1B3 | Homo sapiens (human) | 0.9772 | |
| Solute carrier organic anion transporter family member 1B1 | Homo sapiens (human) | 0.9772 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (28.13) | 29.6817 |
| 2010's | 15 (46.88) | 24.3611 |
| 2020's | 8 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gust, R; Obexer, P; Salcher, S; Schoepf, AM | 1 |
| Masonson, HN; Schwocho, LR | 1 |
| Kirch, W; Laeis, P; Püchler, K | 1 |
| Ikeda, U; Mano, H; Ohki, R; Shimada, K; Ueno, S; Yamamoto, K | 1 |
| Fujita, M; Hirata, A; Hori, M; Kitakaze, M; Liao, Y; Minamino, T; Nagamachi, Y; Nakatani, T; Ogawa, S; Okada, K; Ozawa, K; Takashima, S; Tomoike, H; Tsukamoto, O; Tsukamoto, Y; Yutani, C | 1 |
| Arakawa, N; Fujimori, I; Inoue, T; Nakamura, H; Shimakawa, E; Shimizu, Y; Toyoshi, T; Yokoyama, T; Yoshigae, Y | 1 |
| Gao, Y; Hisaoka, M; Shiga, H; Wada, DR; Yoshihara, K | 1 |
| Adachi, M; Adachi, Y; Hu, Z; Kamiyama, E; Kondo, T; Kusuhara, H; Maeda, K; Nakazawa, H; Okano, T; Schuetz, JD; Shiroyanagi, Y; Sugiyama, D; Sugiyama, Y; Yamada, A | 1 |
| Allison, M; Bathala, MS; Haworth, S; Heyrman, R; Lee, J; Noveck, R; Rohatagi, S; Rubets, I; Salazar, DE; Shenouda, M | 1 |
| Arakawa, K; Kuramoto, K; Tanigawara, Y; Yoshihara, K | 1 |
| Benndorf, RA; Böger, RH; Divac, N; Haefeli, WE; Herzog, M; Sauer, A; Schwedhelm, E; Weiss, J | 1 |
| Chang, JS; Cho, YJ; Choi, WK; Choi, YW; Chung, HJ; El-Gamal, MI; Jeon, HR; Kim, HI; Lee, BS; Lee, J; Lee, WS; Lee, YS; Oh, CH; Park, JH | 1 |
| Elshafeey, AH; Hathout, RM | 1 |
| Janssen, J; Mulder, CJ; Nijeboer, P; van Beurden, YH; Verbeek, WH | 1 |
| Lopez-Piñeiro, S; Puga-Gimenez, M; Ulla-Rocha, JL | 1 |
| Brazier, JE; Guest, JF; Haag, U; Marques da Silva, P; Soro, M | 1 |
| Araújo, TE; Borba, PB; da Silva, AI; de Araújo Júnior, RF; de Araújo, AA; de Souza, FH; Nogueira, AC; Saldanha, TS | 1 |
| Gonzalo, DH; Martelli, MG; Naik, DK; Pannu, D; Sharma, AK | 1 |
| Kodati, D; Kotakonda, HK; Yellu, N | 1 |
| Battistoni, A; Coluccia, R; Mastromarino, V; Santolamazza, C; Tocci, G; Volpe, M | 2 |
| Costa, FV | 1 |
| Srinivas, NR | 1 |
| van der Merwe, WM | 1 |
| Gabb, GM; Moore, K; Shukla, N | 1 |
| Chockalingam, KC; Jayagopal, PB; Khan, MY; Mane, A; Mehta, S; Oomman, A; Pandit, S; Ramakrishnan, A; Shah, S | 1 |
| Adachi, O; Akiyama, M; Kumagai, K; Motoyoshi, N; Saiki, Y; Sasaki, K; Sato, M; Sugawara, Y | 1 |
| Ergur, BU; Karasulu, E; Komesli, Y | 1 |
| Chen, SJ; Chian, CF; Huang, HC; Liaw, WJ; Shih, CC; Tsai, HJ; Tsao, CM; Wu, CC | 1 |
| Burnier, M; Redon, J; Volpe, M | 1 |
| Hong, JH; Hyun, D; Kim, GH; Kim, HL; Kim, W; Lim, S; Min, KW; Oh, J; Park, SD; Shin, J | 1 |
5 review(s) available for olmesartan and olmesartan medoxomil
| Article | Year |
|---|---|
Population pharmacokinetics of olmesartan following oral administration of its prodrug, olmesartan medoxomil: in healthy volunteers and hypertensive patients.
Topics: Administration, Oral; Adult; Angiotensin II Type 1 Receptor Blockers; Creatinine; Europe; Female; Healthy Volunteers; Humans; Hypertension; Imidazoles; Japan; Linear Models; Male; Middle Aged; Models, Biological; Olmesartan Medoxomil; Prodrugs; Retrospective Studies; Tetrazoles; United States | 2005 |
Triple Combination Therapies Based on Olmesartan: A Personalized Therapeutic Approach to Improve Blood Pressure Control.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Drug Therapy, Combination; Humans; Hypertension; Imidazoles; Olmesartan Medoxomil; Precision Medicine; Renin-Angiotensin System; Tetrazoles; Time Factors; Treatment Outcome | 2017 |
Monotherapy and Dual Combination Therapies Based on Olmesartan: A Comprehensive Strategy to Improve Blood Pressure Control.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Drug Therapy, Combination; Humans; Hypertension; Imidazoles; Olmesartan Medoxomil; Tetrazoles; Time Factors; Treatment Outcome | 2017 |
Improving Adherence to Treatment and Reducing Economic Costs of Hypertension: The Role of Olmesartan-Based Treatment.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Cost Savings; Cost-Benefit Analysis; Drug Costs; Drug Substitution; Drug Therapy, Combination; Drugs, Generic; Humans; Hypertension; Imidazoles; Medication Adherence; Olmesartan Medoxomil; Tetrazoles; Time Factors; Treatment Outcome | 2017 |
Single-Pill Combination with Three Antihypertensive Agents to Improve Blood Pressure Control in Hypertension: Focus on Olmesartan-Based Combinations.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Drug Therapy, Combination; Humans; Hydrochlorothiazide; Hypertension; Leukemia, Myeloid, Acute; Olmesartan Medoxomil | 2023 |
3 trial(s) available for olmesartan and olmesartan medoxomil
| Article | Year |
|---|---|
Pharmacokinetics of CS-866, a new angiotensin II receptor blocker, in healthy subjects.
Topics: Administration, Oral; Adult; Angiotensin Receptor Antagonists; Area Under Curve; Biological Availability; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Humans; Hypotension; Imidazoles; Infusions, Intravenous; Liver; Male; Metabolic Clearance Rate; Musculoskeletal Diseases; Olmesartan Medoxomil; Pain; Tablets; Tetrazoles; Transaminases | 2001 |
Comparative pharmacodynamics of olmesartan and azelnidipine in patients with hypertension: a population pharmacokinetic/pharmacodynamic analysis.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Azetidinecarboxylic Acid; Blood Pressure; Calcium Channel Blockers; Circadian Rhythm; Clinical Laboratory Techniques; Cross-Over Studies; Dihydropyridines; Female; Humans; Hypertension; Imidazoles; Individuation; Male; Middle Aged; Olmesartan Medoxomil; Population Groups; Tetrazoles | 2009 |
Health-related quality of life impact of a triple combination of olmesartan medoxomil, amlodipine besylate and hydrochlorotiazide in subjects with hypertension.
Topics: Adult; Aged; Amlodipine; Analysis of Variance; Antihypertensive Agents; Drug Combinations; Female; Humans; Hydrochlorothiazide; Hypertension; Imidazoles; Male; Middle Aged; Olmesartan Medoxomil; Quality of Life; Tetrazoles; Treatment Outcome | 2015 |
24 other study(ies) available for olmesartan and olmesartan medoxomil
| Article | Year |
|---|---|
Identification and development of non-cytotoxic cell death modulators: Impact of sartans and derivatives on PPARγ activation and on growth of imatinib-resistant chronic myelogenous leukemia cells.
Topics: Animals; Cell Death; Cell Proliferation; Chlorocebus aethiops; COS Cells; Drug Design; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; PPAR gamma; Structure-Activity Relationship; Telmisartan | 2020 |
The pharmacokinetic and metabolic profile of olmesartan medoxomil limits the risk of clinically relevant drug interaction.
Topics: Administration, Oral; Adult; Aluminum Hydroxide; Biological Availability; Blood; Digoxin; Dose-Response Relationship, Drug; Drug Combinations; Drug Interactions; Humans; Hydrolysis; Imidazoles; Injections, Intravenous; Magnesium Hydroxide; Male; Olmesartan Medoxomil; Tetrazoles; Warfarin | 2001 |
Effects of olmesartan, an angiotensin II receptor blocker, on mechanically-modulated genes in cardiac myocytes.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Cells, Cultured; Gene Expression Regulation; Imidazoles; Myocytes, Cardiac; Oligonucleotide Array Sequence Analysis; Olmesartan Medoxomil; Rats; Receptor, Angiotensin, Type 1; Reverse Transcriptase Polymerase Chain Reaction; Stress, Mechanical; Tetrazoles | 2003 |
Prolonged endoplasmic reticulum stress in hypertrophic and failing heart after aortic constriction: possible contribution of endoplasmic reticulum stress to cardiac myocyte apoptosis.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Aortic Valve Stenosis; Apoptosis; Cardiomegaly; Cells, Cultured; Disease Models, Animal; Disease Progression; Endoplasmic Reticulum; Gene Expression Regulation; Heart Failure; Humans; Imidazoles; Ligation; Male; Mice; Mice, Inbred C57BL; Molecular Chaperones; Myocytes, Cardiac; Natriuretic Peptide, Brain; Olmesartan Medoxomil; Rats; Rats, Inbred WKY; RNA, Messenger; Signal Transduction; Stress, Physiological; Tetrazoles; Thapsigargin; Tunicamycin | 2004 |
Pharmacological and pharmacokinetic study of olmesartan medoxomil in animal diabetic retinopathy models.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Area Under Curve; Benzimidazoles; Biphenyl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Disease Models, Animal; Dose-Response Relationship, Drug; Electroretinography; Glycated Hemoglobin; Heart Rate; Hypertension; Hypoxia; Imidazoles; Male; Olmesartan Medoxomil; Oxygen; Rats; Rats, Inbred SHR; Retinal Neovascularization; Tetrazoles | 2005 |
Multiple human isoforms of drug transporters contribute to the hepatic and renal transport of olmesartan, a selective antagonist of the angiotensin II AT1-receptor.
Topics: Adenosine Triphosphate; Angiotensin II Type 1 Receptor Blockers; Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cell Line; Dogs; Dose-Response Relationship, Drug; Estrone; Female; Hepatocytes; Humans; Imidazoles; In Vitro Techniques; Kidney; Kinetics; Liver; Liver-Specific Organic Anion Transporter 1; Membrane Transport Proteins; Mice; Mice, Knockout; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Olmesartan Medoxomil; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; p-Aminohippuric Acid; Penicillin G; Probenecid; Prodrugs; Protein Binding; Protein Isoforms; Sincalide; Solute Carrier Organic Anion Transporter Family Member 1B3; Tetrazoles; Transfection | 2007 |
Pharmacokinetics of amlodipine and olmesartan after administration of amlodipine besylate and olmesartan medoxomil in separate dosage forms and as a fixed-dose combination.
Topics: Adolescent; Adult; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Biological Availability; Calcium Channel Blockers; Clinical Trials, Phase I as Topic; Drug Combinations; Drug Interactions; Humans; Imidazoles; Middle Aged; Olmesartan Medoxomil; Randomized Controlled Trials as Topic; Tetrazoles; Therapeutic Equivalency; Young Adult | 2008 |
Interaction of angiotensin receptor type 1 blockers with ATP-binding cassette transporters.
Topics: Acrylates; Angiotensin II Type 1 Receptor Blockers; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP-Binding Cassette Transporters; Benzimidazoles; Biological Transport; Biphenyl Compounds; Digoxin; Fluoresceins; Humans; Hypertension; Imidazoles; Irbesartan; Losartan; Membrane Transport Proteins; Mice; Multidrug Resistance-Associated Protein 2; Olmesartan Medoxomil; Tetrazoles; Thiophenes | 2010 |
Novel amides and esters prodrugs of olmesartan: Synthesis, bioconversion, and pharmacokinetic evaluation.
Topics: Administration, Oral; Amides; Animals; Esters; Imidazoles; Male; Olmesartan Medoxomil; Prodrugs; Rats; Rats, Sprague-Dawley; Tetrazoles | 2010 |
[Hypertension: improved therapy adherence after switch to a fixed drug combinations].
Topics: Amlodipine; Antihypertensive Agents; Controlled Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Combinations; Drug Substitution; Germany; Humans; Hydrochlorothiazide; Hypertension; Imidazoles; Medication Adherence; Olmesartan Medoxomil; Tetrazoles | 2012 |
Development and characterization of colloidal soft nano-carriers for transdermal delivery and bioavailability enhancement of an angiotensin II receptor blocker.
Topics: Administration, Cutaneous; Angiotensin Receptor Antagonists; Animals; Biological Availability; Chemistry, Pharmaceutical; Colloids; Drug Carriers; Drug Delivery Systems; Emulsions; Humans; Hydrogen-Ion Concentration; Imidazoles; Nanoparticles; Olmesartan Medoxomil; Particle Size; Skin; Solubility; Swine; Tablets; Tetrazoles | 2012 |
[Diarrhoea and malabsorption due to olmesartan use].
Topics: Antihypertensive Agents; Atrophy; Celiac Disease; Diagnosis, Differential; Diarrhea; Humans; Hypertension; Imidazoles; Male; Middle Aged; Netherlands; Olmesartan Medoxomil; Tetrazoles | 2014 |
[Acute renal failure secondary to diarrhea due to sprue like-enteropathy associated with olmesartan].
Topics: Acute Kidney Injury; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Celiac Disease; Diagnosis, Differential; Diarrhea; Endoscopy, Gastrointestinal; Female; Humans; Imidazoles; Malabsorption Syndromes; Olmesartan Medoxomil; Tetrazoles | 2015 |
In a methotrexate-induced model of intestinal mucositis, olmesartan reduced inflammation and induced enteropathy characterized by severe diarrhea, weight loss, and reduced sucrose activity.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Anti-Inflammatory Agents; Antimetabolites, Antineoplastic; Diarrhea; Disease Models, Animal; Imidazoles; Inflammation; Interleukin-1beta; Intestinal Mucosa; Intestine, Small; Male; Methotrexate; Mucositis; Neoplasms; Olmesartan Medoxomil; Rats, Wistar; Sucrose; Tetrazoles; Tumor Necrosis Factor-alpha; Weight Loss | 2015 |
An atypical case of chronic diarrhoea: olmesartan-induced sprue-like enteropathy.
Topics: Aged, 80 and over; Atrophy; Celiac Disease; Diarrhea; Female; Humans; Imidazoles; Intestinal Diseases; Intestines; Olmesartan Medoxomil; Tetrazoles | 2015 |
Population Pharmacokinetic Modeling of Olmesartan, the Active Metabolite of Olmesartan Medoxomil, in Patients with Hypertension.
Topics: Absorption, Physiological; Adult; Age Factors; Aged; Antihypertensive Agents; Biological Variation, Population; Body Surface Area; Humans; Hypertension; Imidazoles; India; Metabolic Clearance Rate; Middle Aged; Models, Biological; Olmesartan Medoxomil; Prodrugs; Tetrazoles | 2017 |
Comments on: "Population Pharmacokinetic Modeling of Olmesartan, the Active Metabolite of Olmesartan Medoxomil, in Patients with Hypertension".
Topics: Blood Pressure; Humans; Hypertension; Imidazoles; Olmesartan Medoxomil; Tetrazoles | 2017 |
Treatment of hypertension in CKD patients with azilsartan/chlorthalidone vs olmesartan/hydrochlorothiazide.
Topics: Antihypertensive Agents; Benzimidazoles; Chlorthalidone; Humans; Hydrochlorothiazide; Hypertension; Imidazoles; Olmesartan Medoxomil; Oxadiazoles; Renal Insufficiency, Chronic; Tetrazoles | 2018 |
Olmesartan-associated duodenal villous atrophy, an emerging clinical issue.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Atrophy; Humans; Hypertension; Imidazoles; Olmesartan Medoxomil; Tetrazoles | 2020 |
Effectiveness of Olmesartan on Blood Pressure Control in Hypertensive Patients in India: A Real World, Retrospective, Observational Study from Electronic Medical Records.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Electronic Health Records; Humans; Hypertension; Imidazoles; India; Olmesartan Medoxomil; Retrospective Studies; Tetrazoles | 2020 |
[Effects of Olmesartan Medoxomil on Patients with Thoracic and Thoracoabdominal Aortic Aneurysm;Evaluation of Anti-hypertensive Effect and Possible Suppression of Aneurysmal Dilation( OLM 40 Study)].
Topics: Antihypertensive Agents; Aortic Aneurysm, Thoracic; Dilatation; Humans; Hypertension; Imidazoles; Olmesartan Medoxomil; Prospective Studies; Tetrazoles | 2020 |
Comparison of Pharmacodynamics and Celiac Effects of Olmesartan Medoxomil Formulations by using Olmesartan-induced Celiac-rat-model.
Topics: Animals; Antihypertensive Agents; Imidazoles; Olmesartan Medoxomil; Rats; Rats, Wistar; Tetrazoles | 2021 |
Olmesartan Ameliorates Organ Injury and Mortality in Rats With Peritonitis-Induced Sepsis.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Cecum; Disease Models, Animal; Humans; Imidazoles; Interleukin-6; Nitric Oxide; Olmesartan Medoxomil; Peritonitis; Rats; Rats, Wistar; Sepsis; Tetrazoles | 2022 |
Real-World Effectiveness and Safety of a Single-Pill Combination of Olmesartan/Amlodipine/Hydrochlorothiazide in Korean Patients with Hypertension and Cardiovascular Risk Factors.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Drug Combinations; Female; Heart Disease Risk Factors; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged; Olmesartan Medoxomil; Prospective Studies; Republic of Korea; Risk Factors; Tetrazoles | 2023 |